Volume 70 January 1977 I Editorials Non-commercial Drugs Any discussion of the research policy of the pharmaceutical industry must take account of two factors that have dominated the last decade: consumerism and inflation. The thalidomide disaster led to a wave of public disenchantment in which pharmaceutical firms were pilloried as indifferent to the safety of their drugs, and in consequence governments throughout the world introduced drug-regulatory agencies. Detailed and prolonged tests were required by the agencies, but in addition the major manufacturers themselves adopted a defensive approach to the development of drugs, for at all costs they wished to avoid the adverse publicity that would result from any suspicion of inadequate safety testing. If anything, testing has become more and more stringent so that nowadays any new drug has to go through several years of animal toxicity studies before equally extensive clinical trials can be started. At the same time inflation has not spared the pharmaceutical industry: in common with other manufacturers, drug firms have found their costs rising rapidly. The result of these two trends has been that the minimum cost of developing and testing a drug is now of the order of £1 million, and it often amounts to much more.
With development costs of this order, it is inevitable that research programmes have become concentrated on drugs for which there is likely to be a large marketand in practice (as became clear at the Medico-Pharmaceutical Forum meeting reported in December, p 885) this means that there is little prospect of research by the pharmaceutical industry into diseases limited to developing countries or into rare diseases. Peptic ulcer, arthritis, and hypertension attract research interest; porphyria does not.
Recently there has been a further reason for disquiet about the problem of providing drugs for patients with rare diseaseshighlighted by Dr John Walshe's difficulties with his patients with the disorder of copper metabolism, Wilson's disease (Walshe 1975) . Twenty years ago, when Walshe first postulated that the chelating agent penicillamine might be an effective treatment for Wilson's disease, he did some simple toxicity tests on rats in his own laboratory, took a test dose himself, and then found little difficulty in persuading the firm of Merck, Sharp & Dohme to provide him with supplies. That was all before the new, cautious attitudes provoked by thalidomide. Unfortunately some of his patients have become intolerant of penicillamine (which, by chance, has become a commercial success from its use in rheumatoid arthritis) and he has had to find an alternative, triethylene tetramine dichloride or trien. This time, however, he has been unable to find any pharmaceutical firm willing to supply him with the drug. It is not difficult to make, nor is it expensive; but quite simply no firm has been willing to accept the risk to its reputation of supplying a drug that has not gone through the full range of conventional toxicity tests and clinical trials.
It would be unfair to blame the Medicines Act for these difficulties, though its provisions do complicate the issue. An individual physician can apply for an exemption from the licensing authority and there are other alternatives, but all leave the doctor concerned carrying the risk of any civil liability for damage caused by the drug. The most satisfactory solutionas became apparent at an informal meeting in Cambridge (Lancet 1976) arranged recently by Dr Walshewould be for the supplies division of the DHSS to hold the licence in such cases, cooperating with the Government chemist for checks on quality control, and supplying the drug through one or more identified hospital pharmacists. A compromise along these lines seems likely in the case of trien; whether a precedent will be established remains to be seen. ANTONY J SMITH Assistant Editor, British Medical Journal
